Entyvio
No structure available
This product's active ingredient could not be matched to a single known compound.
Registration
- Applicants
- 1
- Registrations
- 1
Applicants and registrations
| Applicant | Brands | Dosages | Registrations | Schedule | Leaflets |
|---|---|---|---|---|---|
| Takeda (Pty) Ltd | Entyvio | 300 mg | 510955 | Not determined | PI |
Variants
| Product | Strength and form | Registration | Status | Schedule | Leaflets |
|---|---|---|---|---|---|
| Entyvio EACH VIAL CONTAINS: VEDOLUZIMAB 300,0 mg | 300 mgConcentrate for solution for infusion | 51095551/24.1/0955Approved 26 November 2025 | Registered | Not determined | PI |
Regulatory status
This product is still scheduled by law even when this site could not determine which tier it falls under. The label carries the S number in a square border; ask a pharmacist if you need to know its schedule.
This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.
Background
SAHPRA documents
These documents come from SAHPRA's PI-PIL repository unless the line under a document says otherwise. Always consult with a healthcare professional for medical advice.